Sponsor
Stephen Cohen
Representative · D-TN
Representative · D-TN
The bill increases transparency and prioritizes societal and medical benefits in drug scheduling—improving predictability and pathways for legitimate medical uses—but its stricter statutory definitions and approval requirements risk slowing regulatory action, limiting responses to non‑fatal harms, and delaying access to emerging therapies.
Patients with chronic conditions and clinicians would gain clearer, objective pathways (FDA/PHS approval, recognized research use, or jurisdictional recognition) for substances to be designated as having an "accepted medical use," facilitating access to therapies and legal clarity for medical treatment.
Law enforcement, regulators, and healthcare providers would have more transparent and legally predictable scheduling standards because the bill creates defined statutory terms (e.g., dependence, abuse, misuse), reducing ambiguity in enforcement and review decisions.
Public-health stakeholders and patients would see societal benefits (medical, scientific, quality-of-life uses) explicitly weighed in scheduling decisions, increasing the chance that potential therapeutic and research benefits are considered alongside risks.
Law enforcement agencies and the public could face delays in controlling emerging harmful substances because tighter statutory definitions may make it harder or slower to schedule or reschedule drugs quickly.
Regulators and clinicians may be limited in restricting substances that cause serious but non‑fatal harms because narrow definitions (e.g., defining "abuse" by intent to cause a use disorder and tying "lack of accepted safety" to death or significant irreversible harm) raise the bar for intervention.
Patients, researchers, and clinicians could experience slower recognition and clinical adoption of novel or off‑label therapies because the statutory requirement for FDA/PHS approval or jurisdictional recognition to establish "accepted medical use" may delay access and complicate research pathways.
Based on analysis of 2 sections of legislative text.
Adds nine statutory definitions to the Controlled Substances Act that change criteria for evaluating medical use, dependence, abuse, misuse, safety under supervision, and societal benefit in scheduling decisions.
Adds a set of statutory definitions to the Controlled Substances Act that change how federal officials assess whether a drug has an "accepted medical use," risks of dependence or abuse, and the "potential benefits to society" when deciding scheduling. The bill inserts nine defined terms and subcriteria into the CSA definitions and signals an intent to clarify the respective roles of the Attorney General and the Secretary of Health and Human Services in scheduling evaluations, though one amendment in the draft is incomplete and provides no final text.
Official title: To amend the Controlled Substances Act to more closely align the Act with modern medical knowledge, terminology, and practices, and for other purposes.
Introduced June 8, 2026 by Stephen Cohen · Last progress June 8, 2026